Protein / target
B-lymphocyte antigen CD20
Protein at a glance
Biological role
Epidermal growth factor receptor binding
Strongest disease association
Leukemia, Lymphocytic, Chronic, B-Cell
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes.
View complete UniProt function annotationHide complete annotation
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739)
Subcellular location
Domains and Gene Ontology detail (20)Hide
Gene Ontology
- Ccell surface
- Cexternal side of plasma membrane
- Cextracellular exosome
- Cextracellular space
- Cplasma membrane
- Cplasma membrane raft
- Fepidermal growth factor receptor binding
- Fidentical protein binding
- Fimmunoglobulin binding
- FMHC class II protein complex binding
- PB cell activation
- PB cell differentiation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·B cell activation
- ·B cell differentiation
- ·B cell proliferation
- ·B cell receptor signaling pathway
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Broader indication categories (1)Hide
Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.
11 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
B-lymphocyte antigen CD20 binding agent
Indicated for Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
B-lymphocyte antigen CD20 binding agent
Indicated for Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Follicular, Neoplasms
B-lymphocyte antigen CD20 binding agent
Indicated for Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Neoplasms
B-lymphocyte antigen CD20 binding agent
Indicated for Lymphoma, Large B-Cell, Diffuse, Neoplasms
B-lymphocyte antigen CD20 binding agent
Indicated for Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene MS4A1
Gene-level evidence surfaced through the gene MS4A1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
18 compounds recorded · 11 approved · 7 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 5 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
- Trial status changed
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Trial results posted
Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
- Trial results posted
A Phase IIIB Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
- Label change
Label change: GLOFITAMAB (BLA761309)
- Label change
Label change: EPCORITAMAB-BYSP (BLA761324)
- Label change
Label change: GLOFITAMAB (BLA761309)
- Indication expanded
Indication expansion: EPCORITAMAB-BYSP (BLA761324)
- New publicationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
- New publicationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
- Safety communication
Drug Safety Update: Ofatumumab: screen for hepatitis B virus before treatment
- Safety communication
Drug Safety Update: Ofatumumab▼: reminder of risk of serious and fatal infusion reactions
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.